These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Factor VIII preparations: need for prospective pharmacovigilance. Vermylen J; Briët E Lancet; 1993 Sep; 342(8873):693-4. PubMed ID: 8103816 [No Abstract] [Full Text] [Related]
7. Factor VIII concentrate for hemophilia: comparison of two heat-treated products. Walker IR; Pai MK; Blair BA; Johnston MA; Birkett NJ; Ofosu FA; Naylor DH CMAJ; 1987 Jan; 136(2):150-2. PubMed ID: 3098401 [TBL] [Abstract][Full Text] [Related]
8. Factor VIII concentrate: what is "high purity"? Schoppmann A; Weber A; Hondl F; Linnau Y Thromb Haemost; 1994 Sep; 72(3):483-4. PubMed ID: 7855803 [No Abstract] [Full Text] [Related]
9. Glycine-precipitated antihemophilic factor concentrates and their clinical use. Wagner RH; Roberts HR; Webster WP; Shanbrom E; Brinkhous KM Thromb Diath Haemorrh Suppl; 1968; 35():41-8. PubMed ID: 5761073 [No Abstract] [Full Text] [Related]
10. [Treatment with plasma concentrates in hemophilia A. State Security and Health Planning Office. Expert Panel]. Sangre (Barc); 1994 Apr; 39(2):157-61. PubMed ID: 8059299 [No Abstract] [Full Text] [Related]
11. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH. Prowse CV Thromb Haemost; 1995 Oct; 74(4):1191-6. PubMed ID: 8560434 [TBL] [Abstract][Full Text] [Related]
12. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Yee TT; Lee CA Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768 [No Abstract] [Full Text] [Related]
13. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations. Toolis F; McKay G; Prowse CV Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169 [TBL] [Abstract][Full Text] [Related]
14. Preparation of and clinical experience with antihemophilic factor concentrates. Johnson AJ; Karpatkin MH; Newman J Thromb Diath Haemorrh Suppl; 1968; 35():49-59. PubMed ID: 5317364 [No Abstract] [Full Text] [Related]
15. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Hubbard AR; Weller LJ; Bevan SA Br J Haematol; 2002 Apr; 117(1):247-8. PubMed ID: 11918563 [No Abstract] [Full Text] [Related]
17. The control and standardization of Factor VIII. Aronson DL; Thomas DP Scand J Haematol Suppl; 1984; 41():71-8. PubMed ID: 6440287 [No Abstract] [Full Text] [Related]
18. Report of the Subcommittee on Human Factor 8 (AHF) Preparations. Wagner RH Thromb Diath Haemorrh Suppl; 1967; 26():371-5. PubMed ID: 6064867 [No Abstract] [Full Text] [Related]
19. Factor VIII international units and reference materials. Bangham DR; Brozović M Thromb Diath Haemorrh; 1974 Mar; 31(1):3-11. PubMed ID: 4836134 [No Abstract] [Full Text] [Related]
20. Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group. BMJ; 1993 Jan; 306(6873):306-7. PubMed ID: 8461649 [No Abstract] [Full Text] [Related] [Next] [New Search]